Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05028374 · OUTCOME

Observed Rate of STRONG POSITIVE Anti-SARS-CoV2 Antibody Response

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
measured 28 days (+/- 3 days) following a booster dose of the Moderna COVID-19 vaccine.

What was measured

A STRONG POSITIVE response is defined in this trial as an anti-SARS-CoV2 IgG antibody titer of at least 2 S/CO 28 days (+/- 3 days) following vaccine administration

Analysis population: Participants who received a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly.

Groups in this outcome

Cohort 1

Multiple myeloma and amyloidosis patients who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.

Cohort 2

Patients with other hematologic malignancies who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.

Cohort 3

Patients with multiple myeloma, amyloidosis, or other hematologic malignancy who had a "weak positive" response to prior COVID-19 vaccine, defined as an anti-spike antibody titer of 1-2 S/CO.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 152
Cohort 250
Cohort 316

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 127Not reportedNot reportedNot reportedNot reported
Cohort 223Not reportedNot reportedNot reportedNot reported
Cohort 315Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        27
      2. group Id
        OG001
        value
        23
      3. group Id
        OG002
        value
        15
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    2. group Id
      OG001
      value
      50
    3. group Id
      OG002
      value
      16
    units
    Participants
description
A STRONG POSITIVE response is defined in this trial as an anti-SARS-CoV2 IgG antibody titer of at least 2 S/CO 28 days (+/- 3 days) following vaccine administration
groups
  1. description
    Multiple myeloma and amyloidosis patients who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.
    id
    OG000
    title
    Cohort 1
  2. description
    Patients with other hematologic malignancies who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.
    id
    OG001
    title
    Cohort 2
  3. description
    Patients with multiple myeloma, amyloidosis, or other hematologic malignancy who had a "weak positive" response to prior COVID-19 vaccine, defined as an anti-spike antibody titer of 1-2 S/CO.
    id
    OG002
    title
    Cohort 3
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who received a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly.
reporting Status
POSTED
time Frame
measured 28 days (+/- 3 days) following a booster dose of the Moderna COVID-19 vaccine.
title
Observed Rate of STRONG POSITIVE Anti-SARS-CoV2 Antibody Response
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice